The 36-month beta value for CLLS is at 3.03. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CLLS is 64.68M, and currently, shorts hold a 0.70% of that float. The average trading volume for CLLS on April 11, 2025 was 363.24K shares.
CLLS) stock’s latest price update
The stock of Cellectis ADR (NASDAQ: CLLS) has increased by 13.82 when compared to last closing price of 1.23.Despite this, the company has seen a gain of 21.74% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-14 that Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril – CFO and Chief Business Officer Andre Choulika – CEO Adrian Kilcoyne – CMO Conference Call Participants Gena Wang – Barclays Jack Allen – Baird Sebastiaan van der Schoot – Kempen Silvan Tuerkcan – Citizens Jack Allen – Baird Hangfei Fu – Jefferies Operator Good day, everyone, and welcome to today’s Cellectis Full Year 2024 Earnings Conference Call.
CLLS’s Market Performance
CLLS’s stock has risen by 21.74% in the past week, with a monthly rise of 8.53% and a quarterly drop of -24.32%. The volatility ratio for the week is 8.52% while the volatility levels for the last 30 days are 6.41% for Cellectis ADR The simple moving average for the last 20 days is 10.79% for CLLS’s stock, with a simple moving average of -23.09% for the last 200 days.
Analysts’ Opinion of CLLS
Many brokerage firms have already submitted their reports for CLLS stocks, with Bryan Garnier repeating the rating for CLLS by listing it as a “Buy.” The predicted price for CLLS in the upcoming period, according to Bryan Garnier is $6 based on the research report published on March 17, 2023 of the previous year 2023.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CLLS reach a price target of $10. The rating they have provided for CLLS stocks is “Outperform” according to the report published on May 18th, 2022.
Wells Fargo gave a rating of “Equal Weight” to CLLS, setting the target price at $16 in the report published on January 06th of the previous year.
CLLS Trading at 2.78% from the 50-Day Moving Average
After a stumble in the market that brought CLLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.58% of loss for the given period.
Volatility was left at 6.41%, however, over the last 30 days, the volatility rate increased by 8.52%, as shares surge +12.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.03% lower at present.
During the last 5 trading sessions, CLLS rose by +20.87%, which changed the moving average for the period of 200-days by -27.98% in comparison to the 20-day moving average, which settled at $1.2632. In addition, Cellectis ADR saw -22.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLLS
Current profitability levels for the company are sitting at:
- -1.44 for the present operating margin
- 1.03 for the gross margin
The net margin for Cellectis ADR stands at -0.89. The total capital return value is set at -0.28. Equity return is now at value -34.08, with -10.12 for asset returns.
Based on Cellectis ADR (CLLS), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -8.05.
Currently, EBITDA for the company is -9.46 million with net debt to EBITDA at 1.45. When we switch over and look at the enterprise to sales, we see a ratio of 1.04. The receivables turnover for the company is 1.8for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.73.
Conclusion
In conclusion, Cellectis ADR (CLLS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
